Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 9
Submit an article Journal homepage
609
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Are monoclonals the way forward to prevent or to treat ventilator-associated pneumonia in the intensive care unit?

Ana Catalina Hernandez Padillaa Inserm, Limoges, France;b Réanimation Polyvalente, CHU Dupuytren, Limoges, France;c Inserm UMR 1092 and Université of Limoges, Limoges, FranceORCID Iconhttps://orcid.org/0000-0003-3464-7294View further author information
ORCID Icon,
Sylvain Meyerc Inserm UMR 1092 and Université of Limoges, Limoges, FranceORCID Iconhttps://orcid.org/0000-0001-7957-6093View further author information
ORCID Icon,
CH Van Werkhovend Department of Epidemiology and Health Economics, UMCU, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-0626-4635View further author information
ORCID Icon,
Marlieke EA de Krakere Département de Médecine, Geneva University Hospitals and Faculty of Medicine, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-0903-8614View further author information
ORCID Icon &
Bruno Françoisa Inserm, Limoges, France;b Réanimation Polyvalente, CHU Dupuytren, Limoges, France;c Inserm UMR 1092 and Université of Limoges, Limoges, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2531-1652View further author information
ORCID Icon
Pages 861-866 | Received 17 May 2023, Accepted 21 Jul 2023, Published online: 29 Jul 2023

References

  • Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (Hap)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50:1700582.
  • Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665–671. doi: 10.1016/S1473-3099(13)70081-1
  • Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703. doi: 10.1038/nrmicro974
  • The Antibody Society. Therapeutic monoclonal approved or in review in the EU or US [Internet]. [cited 2023 Feb 5]. Available from: https://www.antibodysociety.org/resources/approved-antibodies/
  • Nagy E, Nagy G, Power CA, et al. Anti-bacterial Monoclonal Antibodies. In: Lim Teditor. Recombinant antibodies for infectious diseases. Cham: Springer International Publishing; 2017. p. 119–153.
  • Jones-Nelson O, Tovchigrechko A, Glover MS, et al. Antibacterial monoclonal antibodies do not disrupt the intestinal microbiome or its function. Antimicrob Agents Chemother. 2020;64(5):e02347–19. doi: 10.1128/AAC.02347-19
  • Zurawski DV, McLendon MK. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics (Basel). 2020;9(4):155. doi: 10.3390/antibiotics9040155
  • François B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit Care Med. 2012;40(8):2320–2326. doi: 10.1097/CCM.0b013e31825334f6
  • Que Y-A, Lazar H, Wolff M, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014;33(10):1861–1867. doi: 10.1007/s10096-014-2156-1
  • Lu Q, Eggimann P, Luyt C-E, et al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. Crit Care. 2014;18(1):R17. doi: 10.1186/cc13697
  • Chastre J, François B, Bourgeois M, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022;26(1):355. doi: 10.1186/s13054-022-04204-9
  • Magyarics Z, Leslie F, Bartko J, et al. Randomized, double-blind, placebo-controlled, single-ascending-dose study of the penetration of a monoclonal antibody combination (ASN100) targeting staphylococcus aureus cytotoxins in the lung epithelial lining fluid of healthy volunteers. Antimicrob Agents Chemother. 2019;63(8):e00350–19. doi: 10.1128/AAC.00350-19
  • François B, Jafri HS, Chastre J, et al. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect Dis. 2021;21(9):1313–1323. doi: 10.1016/S1473-3099(20)30995-6
  • François B, Mercier E, Gonzalez C, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive care Med. 2018;44(11):1787–1796. doi: 10.1007/s00134-018-5229-2
  • François B, Jafri HS, Pavlov O, et al. Efficacy and safety profile of tosatoxumab (AR-301), a novel anti-Staphylococcus aureus monoclonal antibody (mAb): results of the phase 3 AR-301-002 (ASAP) study of adjunctive treatment of S. aureus ventilator associated pneumonia (VAP) in mechanically ventilated, intensive care unit (ICU) patients Abstract presented at. 33rd ed. Copenhagen Denmark: ECCMID; 2023 Apr 15-18.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.